ATE348888T1 - Eine den gp41-zwischenzustand imitierende struktur bildendes polypeptid-antigen - Google Patents

Eine den gp41-zwischenzustand imitierende struktur bildendes polypeptid-antigen

Info

Publication number
ATE348888T1
ATE348888T1 AT02783174T AT02783174T ATE348888T1 AT E348888 T1 ATE348888 T1 AT E348888T1 AT 02783174 T AT02783174 T AT 02783174T AT 02783174 T AT02783174 T AT 02783174T AT E348888 T1 ATE348888 T1 AT E348888T1
Authority
AT
Austria
Prior art keywords
intermediate state
mimicing
polypeptide antigen
polypeptide
antigen forming
Prior art date
Application number
AT02783174T
Other languages
English (en)
Inventor
Michel Chevalier
Habib Raphaelle El
Tino Krell
Regis Sodoyer
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0112806A external-priority patent/FR2830534B1/fr
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Application granted granted Critical
Publication of ATE348888T1 publication Critical patent/ATE348888T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02783174T 2001-10-05 2002-09-18 Eine den gp41-zwischenzustand imitierende struktur bildendes polypeptid-antigen ATE348888T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0112806A FR2830534B1 (fr) 2001-10-05 2001-10-05 Antigene polypeptidique formant une structure mimant l'etat intermediaire de gp41.
US34790901P 2001-11-07 2001-11-07

Publications (1)

Publication Number Publication Date
ATE348888T1 true ATE348888T1 (de) 2007-01-15

Family

ID=26213208

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02783174T ATE348888T1 (de) 2001-10-05 2002-09-18 Eine den gp41-zwischenzustand imitierende struktur bildendes polypeptid-antigen

Country Status (10)

Country Link
US (1) US6821723B2 (de)
EP (1) EP1442124B1 (de)
AT (1) ATE348888T1 (de)
CA (1) CA2462710C (de)
CY (1) CY1106017T1 (de)
DE (1) DE60216958T2 (de)
DK (1) DK1442124T3 (de)
ES (1) ES2275926T3 (de)
PT (1) PT1442124E (de)
WO (1) WO2003042388A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0422439D0 (en) * 2004-10-08 2004-11-10 European Molecular Biology Lab Embl Inhibitors of infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2781676B1 (fr) * 1998-07-31 2004-04-02 Pasteur Merieux Serums Vacc Trimere du produit d'expression du gene env de hiv
EP1149115A4 (de) * 1999-01-08 2005-11-02 Panacos Pharmaceuticals Inc Verfahren zum hervorrufen von breit wirksamen, neutralisierenden antikörpern, die gegen gp41 von hiv-1 gerichtet sind.
EP1237912B1 (de) * 1999-12-16 2007-12-12 Whitehead Institute For Biomedical Research Funf-helix protein
WO2001070262A2 (en) * 2000-03-17 2001-09-27 Panacos Pharmaceuticals, Inc. A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins

Also Published As

Publication number Publication date
CA2462710C (en) 2011-05-17
PT1442124E (pt) 2007-02-28
CA2462710A1 (en) 2003-05-22
EP1442124B1 (de) 2006-12-20
DE60216958D1 (de) 2007-02-01
US20030138445A1 (en) 2003-07-24
WO2003042388A1 (fr) 2003-05-22
EP1442124A1 (de) 2004-08-04
ES2275926T3 (es) 2007-06-16
DE60216958T2 (de) 2007-10-04
CY1106017T1 (el) 2011-04-06
DK1442124T3 (da) 2007-04-10
US6821723B2 (en) 2004-11-23

Similar Documents

Publication Publication Date Title
DE60110822D1 (de) Zubereitung zur immunisierung gegen den aids-virus
ATE542829T1 (de) Impfstoff
ID30497A (id) Peptida hiv, antigen, komposisi vaksin, kit imunoasai dan metoda untuk mendeteksi antibodi yang diinduksi oleh hiv
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
WO2002020554A3 (en) Hiv peptides from conserved regions in gag p17 and 924 and their application in e.g. vaccines
TR199801722T2 (xx) Peptit imm�nojenler.
IL221708A0 (en) Polyclonal goat anti-hla class ii antibody for treatment of disease involving proliferative immune response
EA200700496A1 (ru) Инактивированная полиомиелитная вакцина, полученная из штамма сейбина вируса полиомиелита
BR0312808A (pt) Proteìna de fusão igg fc/hiv-gp120/c3d
EP0881910A4 (de) Verwendung von immunokonjugaten zur erhöhung der effektivität von mehrstufigen kaskaden-impfstoffen
WO2001060404A3 (en) Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens
DE60222296D1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
DE69327529D1 (de) Immunologisch mit HLA homologe HIV Protein Epitope
WO2003015702A3 (en) Epitopes of human immunodeficiency virus-1
ATE348888T1 (de) Eine den gp41-zwischenzustand imitierende struktur bildendes polypeptid-antigen
WO2004053100A3 (en) Immunogenic mutant human immunodeficiency virus gp120 polypeptides, and methods of using same
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
DK1368478T3 (da) Polypeptid, der fremkalder HIV-neutraliserende antistoffer
DE69233271D1 (de) Therapeutischer- und präventivimpfstoff gegen hiv
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
WO2002085409A3 (en) Methods and compositions for inducing an immune response to an antigen
HUP0301085A2 (hu) Új peptid és alkalmazása szelektálási eljárásra
FR2839721B1 (fr) Antigene polypeptidique induisant des anticorps neutralisant le vih
JP2004532198A5 (de)
FR2818648B1 (fr) Antigenes proteiques inducteurs d'anticorps neutralisant le virus vih

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1442124

Country of ref document: EP